User login
Key clinical point: The combination of oral metronomic capecitabine and pyrotinib showed acceptable efficacy and tolerable safety in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).
Major finding: Patients receiving metronomic capecitabine + pyrotinib had an objective response rate of 34.7% and a clinical benefit rate of 81.6%, with 4.1% and 30.6% of patients achieving complete and partial responses, respectively, which lasted for ≥ 24 weeks. The most common grade 3 adverse events were hand-foot syndrome (12.2%), diarrhea (12.2%), vomiting (4.1%), and nausea (2.0%).
Study details: Findings are from a prospective, single-arm phase 2 trial including 49 patients with HER2+ metastatic BC who received 500 mg oral metronomic capecitabine 3 times per day and 400 mg pyrotinib per day.
Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.
Source: He M, Liu J, et al. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial. Breast. 2023;72:105381 (Sep 19). doi: 10.1016/j.breast.2023.103581
Key clinical point: The combination of oral metronomic capecitabine and pyrotinib showed acceptable efficacy and tolerable safety in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).
Major finding: Patients receiving metronomic capecitabine + pyrotinib had an objective response rate of 34.7% and a clinical benefit rate of 81.6%, with 4.1% and 30.6% of patients achieving complete and partial responses, respectively, which lasted for ≥ 24 weeks. The most common grade 3 adverse events were hand-foot syndrome (12.2%), diarrhea (12.2%), vomiting (4.1%), and nausea (2.0%).
Study details: Findings are from a prospective, single-arm phase 2 trial including 49 patients with HER2+ metastatic BC who received 500 mg oral metronomic capecitabine 3 times per day and 400 mg pyrotinib per day.
Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.
Source: He M, Liu J, et al. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial. Breast. 2023;72:105381 (Sep 19). doi: 10.1016/j.breast.2023.103581
Key clinical point: The combination of oral metronomic capecitabine and pyrotinib showed acceptable efficacy and tolerable safety in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).
Major finding: Patients receiving metronomic capecitabine + pyrotinib had an objective response rate of 34.7% and a clinical benefit rate of 81.6%, with 4.1% and 30.6% of patients achieving complete and partial responses, respectively, which lasted for ≥ 24 weeks. The most common grade 3 adverse events were hand-foot syndrome (12.2%), diarrhea (12.2%), vomiting (4.1%), and nausea (2.0%).
Study details: Findings are from a prospective, single-arm phase 2 trial including 49 patients with HER2+ metastatic BC who received 500 mg oral metronomic capecitabine 3 times per day and 400 mg pyrotinib per day.
Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.
Source: He M, Liu J, et al. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial. Breast. 2023;72:105381 (Sep 19). doi: 10.1016/j.breast.2023.103581